Fourth Circuit Holds cGMP Violations Do Not Create False Claims Under Medicare and Medicaid - wilmerhale.com
Fourth Circuit ruled that cGMP violations alone do not establish False Claims Act liability under Medicare/Medicaid, reducing FCA exposure for drug manufacturers but not eliminating other regulatory risks.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 1, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities (503B) that are subject to cGMP requirements and participate in Medicare/Medicaid. should confirm how it applies to their specific situation before acting. There is a time constraint attached: No specific deadline provided; monitor for further developments or potential appeals.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The Fourth Circuit held that cGMP violations do not automatically create false claims under Medicare/Medicaid, meaning plaintiffs cannot use such violations as a basis for FCA liability in that circuit.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities (503B) that are subject to cGMP requirements and participate in Medicare/Medicaid.
What you must do
Review current compliance programs and litigation strategies to account for this ruling; consider its impact on any pending or potential FCA cases.
Deadline
No specific deadline provided; monitor for further developments or potential appeals.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Supreme Court Temporarily Blocks Ruling Barring Telehealth And Pharmacy Access To Mifepristone - Health Affairs
- FDA Proposes to Eliminate "Adequate Provision" for Broadcast Prescription Drug Advertising - foleyhoag.com
- FDA Warning Letter Cites Significant CGMP Violations at Tom’s of Maine Factory - Happi | Household And Personal Products Industry
- Connecticut Law Imposes New Requirements on Pharmaceutical Manufacturers, Defined to Include Device and Cosmetic Manufacturers, that Employ “Pharmaceutical Sales Representatives” - mintz.com
- FDA Issues Warning to Sanofi About API CGMP Deviations, Puts Clinical Hold on Atara Immunotherapies - biopharminternational.com